Table 2.

Postinfusion outcomes by cytogenetic group

High riskIntermediate riskFavorable risk
MLL (KMT2Ar)
(n = 25)		Ph+
(n = 18)		Ph-like
(n = 19)		Hypodiploid
(n = 8)		TCF3/HLF
(n = 4)		iAMP21
(n = 10)		IZF1
(n = 10)		TCF3/PBX1
(n = 8)		Hyperdiploid
(n = 30)		ETV6/RUNX1
(n = 13)		Uninformative
(n = 86)
Disease response            
 Complete response 23 (92%) 18 (100%) 16 (84%) 8 (100%) 4 (100%) 10 (100%) 8 (80%) 6 (75%) 29 (97%) 13 (100%) 83 (97%) 
 No response 1 (4.0%) 0 (0%) 2 (11%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 2 (25%) 1 (3.3%) 0 (0%) 3 (3.5%) 
 Inevaluable* 1 (4.0%) 0 (0%) 1 (5.3%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Patients with relapse, n (%) 12 (48%) 2 (11%) 3 (16%) 5 (62%) 2 (50%) 2 (20%) 2 (20%) 4 (50%) 6 (20%) 8 (62%) 32 (37%) 
 CD19− 7† 2 2 3 1 0 2 2 3 4 16‡ 
 CD19+ 4 0 0 1 1 2 0 2 2 4 14 
Months of follow-up, median (interquartile range) 26 (24, 43) 24 (21, 60) 30 (15, 45) 28 (20, 43) 
High riskIntermediate riskFavorable risk
MLL (KMT2Ar)
(n = 25)		Ph+
(n = 18)		Ph-like
(n = 19)		Hypodiploid
(n = 8)		TCF3/HLF
(n = 4)		iAMP21
(n = 10)		IZF1
(n = 10)		TCF3/PBX1
(n = 8)		Hyperdiploid
(n = 30)		ETV6/RUNX1
(n = 13)		Uninformative
(n = 86)
Disease response            
 Complete response 23 (92%) 18 (100%) 16 (84%) 8 (100%) 4 (100%) 10 (100%) 8 (80%) 6 (75%) 29 (97%) 13 (100%) 83 (97%) 
 No response 1 (4.0%) 0 (0%) 2 (11%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 2 (25%) 1 (3.3%) 0 (0%) 3 (3.5%) 
 Inevaluable* 1 (4.0%) 0 (0%) 1 (5.3%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Patients with relapse, n (%) 12 (48%) 2 (11%) 3 (16%) 5 (62%) 2 (50%) 2 (20%) 2 (20%) 4 (50%) 6 (20%) 8 (62%) 32 (37%) 
 CD19− 7† 2 2 3 1 0 2 2 3 4 16‡ 
 CD19+ 4 0 0 1 1 2 0 2 2 4 14 
Months of follow-up, median (interquartile range) 26 (24, 43) 24 (21, 60) 30 (15, 45) 28 (20, 43) 
*

Three patients died prior to day 28 evaluation from sequelae of cytokine release syndrome, coagulopathy, and infection without clear evidence of progressive disease.

†

Includes 4 patients with lineage switch.

‡

Includes 1 patient with lineage switch.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal